{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:45:03Z","timestamp":1784555103360,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.03.060","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T03:14:20Z","timestamp":1649042060000},"page":"2960-2969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates"],"prefix":"10.1016","volume":"40","author":[{"given":"Jewell N.","family":"Walters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Schouest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Reuschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Parzych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Maricic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony N.","family":"Gary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Purwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane M.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Elwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeena","family":"Eblimit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Frase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz I.","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Generotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Joseph Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor R.F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.03.060_b0005","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3389\/fmicb.2020.00658","article-title":"The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses","volume":"11","author":"Tse","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2022.03.060_b0010","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-020-03370-6","article-title":"How COVID vaccines are being divvied up around the world","author":"Mullard","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.060_b0015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat Med"},{"issue":"7857","key":"10.1016\/j.vaccine.2022.03.060_b0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.vaccine.2022.03.060_b0025","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2022.03.060_b0030","doi-asserted-by":"crossref","unstructured":"Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021:2021.01.25.427948. doi: 10.1101\/2021.01.25.427948.","DOI":"10.1101\/2021.01.25.427948"},{"issue":"5","key":"10.1016\/j.vaccine.2022.03.060_b0035","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.060_b0040","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta)","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"Variant N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.03.060_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.060_b0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"issue":"41","key":"10.1016\/j.vaccine.2022.03.060_b0055","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1016\/j.vaccine.2017.02.015","article-title":"Vaccine development for emerging virulent infectious diseases","volume":"35","author":"Maslow","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.03.060_b0060","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/infdis\/jiz132","article-title":"Intradermal SynCon(R) Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers","volume":"220","author":"Tebas","year":"2019","journal-title":"J Infect Dis"},{"issue":"34","key":"10.1016\/j.vaccine.2022.03.060_b0065","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1016\/j.vaccine.2021.06.057","article-title":"One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model","volume":"39","author":"Gooch","year":"2021","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.03.060_b0070","doi-asserted-by":"crossref","first-page":"100420","DOI":"10.1016\/j.xcrm.2021.100420","article-title":"Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model","volume":"2","author":"Patel","year":"2021","journal-title":"Cell Rep Med"},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.060_b0075","doi-asserted-by":"crossref","first-page":"102699","DOI":"10.1016\/j.isci.2021.102699","article-title":"A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens","volume":"24","author":"Gary","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2022.03.060_b0080","doi-asserted-by":"crossref","unstructured":"Reed CC, Schultheis K, Andrade VM, Kalia R, Tur J, Schouest B, et al. Design, immunogenicity and efficacy of a Pan-SARS-CoV-2 synthetic DNA vaccine. bioRxiv. 2021:2021.05.11.443592. doi: 10.1101\/2021.05.11.443592.","DOI":"10.1101\/2021.05.11.443592"},{"key":"10.1016\/j.vaccine.2022.03.060_b0085","doi-asserted-by":"crossref","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2022.03.060_b0090","doi-asserted-by":"crossref","unstructured":"Mammen MP, Tebas P, Agnes J, Giffear M, Kraynyak KA, Blackwood E, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. medRxiv. 2021:2021.05.07.21256652. doi: 10.1101\/2021.05.07.21256652.","DOI":"10.1101\/2021.05.07.21256652"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.060_b0095","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: Mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.03.060_b0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"46","key":"10.1016\/j.vaccine.2022.03.060_b0105","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1016\/j.vaccine.2011.08.001","article-title":"Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania","volume":"29","author":"Bakari","year":"2011","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.03.060_b0110","doi-asserted-by":"crossref","first-page":"e24517","DOI":"10.1371\/journal.pone.0024517","article-title":"Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial","volume":"6","author":"Koblin","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vaccine.2022.03.060_b0115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.03.060_b0120","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/mt.2010.112","article-title":"Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques","volume":"18","author":"Hirao","year":"2010","journal-title":"Mol Ther"},{"issue":"7830","key":"10.1016\/j.vaccine.2022.03.060_b0125","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.vaccine.2022.03.060_b0130","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T Follicular Helper Cell Biology: A Decade of Discovery and Diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.vaccine.2022.03.060_b0135","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.060_b0140","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.chom.2021.06.001","article-title":"A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses","volume":"29","author":"Tauzin","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"6493","key":"10.1016\/j.vaccine.2022.03.060_b0145","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1126\/science.abb5793","article-title":"Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period","volume":"368","author":"Kissler","year":"2020","journal-title":"Science"},{"issue":"7819","key":"10.1016\/j.vaccine.2022.03.060_b0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/d41586-020-02278-5","article-title":"How the pandemic might play out in 2021 and beyond","volume":"584","author":"Scudellari","year":"2020","journal-title":"Nature"},{"issue":"6529","key":"10.1016\/j.vaccine.2022.03.060_b0155","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"issue":"54","key":"10.1016\/j.vaccine.2022.03.060_b0160","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf8891","article-title":"Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence","volume":"5","author":"Hartley","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.060_b0165","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination","volume":"384","author":"Widge","year":"2021","journal-title":"N Engl J Med"},{"issue":"60","key":"10.1016\/j.vaccine.2022.03.060_b0170","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj3684","article-title":"SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques","volume":"6","author":"Garrido","year":"2021","journal-title":"Sci Immunol"},{"issue":"59","key":"10.1016\/j.vaccine.2022.03.060_b0175","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2022.03.060_b0180","doi-asserted-by":"crossref","unstructured":"Andrade VM, Christensen-Quick A, Agnes J, Tur J, Reed C, Kalia R, et al. INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants. bioRxiv. 2021:2021.04.14.439719. doi: 10.1101\/2021.04.14.439719.","DOI":"10.1101\/2021.04.14.439719"},{"issue":"20","key":"10.1016\/j.vaccine.2022.03.060_b0185","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2022.03.060_b0190","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.03.060_b0195","doi-asserted-by":"crossref","unstructured":"Wu K, Choi A, Koch M, Ma L, Hill A, Nunna N, et al. Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster. medRxiv. 2021:2021.05.05.21256716. doi: 10.1101\/2021.05.05.21256716.","DOI":"10.1101\/2021.05.05.21256716"},{"key":"10.1016\/j.vaccine.2022.03.060_b0200","article-title":"Heterologous SARS-CoV-2 Booster Vaccinations \u2013 Preliminary Report","author":"Atmar","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2022.03.060_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.03.060_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00420-5","article-title":"Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2","author":"Tenbusch","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2022.03.060_b0215","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJMc2110716","article-title":"Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination","volume":"385","author":"Normark","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.03.060_b0220","doi-asserted-by":"crossref","unstructured":"Kraynyak KA, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, et al. SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. medRxiv. 2021:2021.10.06.21264584. doi: 10.1101\/2021.10.06.21264584.","DOI":"10.1101\/2021.10.06.21264584"},{"issue":"7867","key":"10.1016\/j.vaccine.2022.03.060_b0230","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.vaccine.2022.03.060_b0235","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cell.2021.01.050","article-title":"Maturation and persistence of the anti-SARS-CoV-2 memory B cell response","volume":"184","author":"Sokal","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2022.03.060_b0240","doi-asserted-by":"crossref","unstructured":"Winklmeier S, Eisenhut K, Taskin D, R\u00fcbsamen H, Schneider C, Eichhorn P, et al. Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. medRxiv. 2021:2021.05.15.21257210. doi: 10.1101\/2021.05.15.21257210.","DOI":"10.1101\/2021.05.15.21257210"},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.060_b0245","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.vaccine.2022.03.060_b0250","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","article-title":"Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med"},{"issue":"7868","key":"10.1016\/j.vaccine.2022.03.060_b0255","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"issue":"10249","key":"10.1016\/j.vaccine.2022.03.060_b0260","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.060_b0265","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41564-020-00824-5","article-title":"Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals","volume":"6","author":"Zhang","year":"2021","journal-title":"Nat Microbiol"},{"issue":"9","key":"10.1016\/j.vaccine.2022.03.060_b0270","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","article-title":"Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19","volume":"26","author":"Juno","year":"2020","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.vaccine.2022.03.060_b0275","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.060_b0280","article-title":"Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.03.060_b0285","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22003681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22003681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:12:01Z","timestamp":1759403521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22003681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":56,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22003681"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.060","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.10.27.466163","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}